COMPOUND DEEP DIVES
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that has attracted substantial interest in the peptide research community for its capacity to amplify endogenous growth hormone (GH) pulses without displacing the normal pulsatile rhythm of secretion. Preclinical investigations and early-phase clinical pharmacology studies have examined CJC-1295 as a tool compound for probing the GH/IGF-1 axis, with particular focus on its two principal forms — a Drug Affinity Complex (DAC) conjugate and a non-DAC variant — each carrying distinct pharmacokinetic profiles relevant to experimental design.
GHRH is a 44-amino-acid hypothalamic peptide that binds the GHRH receptor (GHRH-R) on somatotroph cells of the anterior pituitary, triggering the synthesis and pulsatile release of GH. Native GHRH is rapidly degraded in plasma — primarily by dipeptidyl peptidase IV (DPP-IV) — with a half-life estimated at less than 10 minutes in vivo. CJC-1295 was developed to address this limitation by introducing targeted amino acid substitutions at positions known to confer DPP-IV resistance, producing a compound with substantially extended biological activity while preserving GHRH-R agonism.
Research by Teichman SL et al. published in the Journal of Clinical Endocrinology & Metabolism (2006) characterized the pharmacokinetics and pharmacodynamics of CJC-1295 in healthy adult subjects, demonstrating dose-dependent increases in mean plasma GH and IGF-1 concentrations over a multi-day observation window — findings that established a foundational pharmacological profile for subsequent animal model investigations. The compound’s receptor selectivity for GHRH-R, coupled with its resistance to enzymatic cleavage, makes it a valuable tool for researchers examining the upstream regulation of the GH/IGF-1 axis.
For researchers also exploring adjacent peptide mechanisms in longevity and cellular repair, the preclinical literature on Epithalon and telomere biology offers a complementary perspective on how peptide compounds modulate aging-related signaling pathways.
One of the most practically significant distinctions in CJC-1295 research concerns the presence or absence of a Drug Affinity Complex (DAC) — a lysine-maleimido propionic acid conjugate that enables covalent binding to circulating albumin. This albumin-binding mechanism dramatically extends the compound’s plasma half-life, shifting it from hours (non-DAC) to approximately six to eight days (DAC form), as reported across multiple pharmacokinetic analyses.
The non-DAC form, sometimes referred to as CJC-1295 without DAC (or Modified GRF 1-29), retains the amino acid substitution profile conferring DPP-IV resistance but lacks albumin conjugation. Its half-life in rodent models has been reported in the range of 30 minutes to two hours, making it more analogous to a physiological GH secretagogue stimulus — producing a discrete, transient GH pulse — while the DAC form produces a sustained elevation in mean GH and IGF-1 levels over days.
This distinction carries meaningful implications for experimental design: researchers studying acute GH secretory dynamics typically favor the non-DAC form, whereas investigations into chronic GH/IGF-1 axis stimulation — such as body composition or longevity-related endpoints — more commonly employ the DAC-conjugated compound.
| Parameter | Native GHRH(1-44) | CJC-1295 No-DAC (Modified GRF 1-29) | CJC-1295 DAC |
|---|---|---|---|
| Plasma half-life | <10 min | ~30 min – 2 hr | ~6–8 days |
| DPP-IV resistance | None | High (substituted residues) | High (substituted residues) |
| Albumin binding | None | None | Yes (covalent, maleimido-DAC) |
| GH release pattern | Acute pulse | Discrete pulse (transient) | Sustained mean elevation |
| IGF-1 axis effect | Brief, minimal | Moderate, pulsatile | Prolonged, cumulative |
| Primary research use | Acute GH secretion studies | GH pulse dynamics, pulsatile models | Chronic GH axis stimulation, body composition, aging models |
Rodent studies examining CJC-1295’s effect on the somatotropic axis have consistently demonstrated dose-dependent elevations in both GH secretory amplitude and circulating IGF-1 concentrations. The GHRH-R signaling cascade initiated by CJC-1295 binding proceeds through Gs-protein coupling, adenylyl cyclase activation, and cAMP-mediated stimulation of GH gene transcription and vesicular release — a mechanism functionally identical to endogenous GHRH but sustained over a markedly longer window.
In murine models, investigators have noted that CJC-1295 (DAC) administered at weekly intervals maintained elevated IGF-1 levels for the duration of multi-week treatment protocols, without apparent desensitization of GHRH-R at the doses studied. This receptor-level observation is particularly relevant to longevity research: the GH/IGF-1 axis is a well-characterized regulator of mammalian lifespan, with studies in long-lived mutant mice (Ames dwarf, Snell dwarf, and growth hormone receptor knockout models) consistently linking reduced somatotropic signaling to extended lifespan — while paradoxically, restoration of youthful GH pulsatility in aged rodents has been associated with improved metabolic and body composition parameters.
Body composition studies in rodent models using chronic GHRH analog administration have reported reductions in total fat mass concurrent with preservation or gains in lean body mass, effects attributed to the lipolytic and anabolic downstream actions of elevated GH and IGF-1. These findings parallel observations from earlier GHRH research and provide mechanistic context for ongoing interest in CJC-1295 as a research probe for somatotropic aging biology.
Researchers interested in the broader landscape of regenerative peptide research may also find the preclinical data on BPC-157 and its tissue repair mechanisms relevant, as both compounds are studied in the context of recovery and anabolic signaling in animal models.
CJC-1295 is a synthetic GHRH analog engineered for resistance to DPP-IV enzymatic degradation, substantially extending its biological half-life relative to native GHRH(1-44). While native GHRH is cleared from plasma within minutes, CJC-1295 (non-DAC) persists for up to two hours, and the DAC-conjugated form for up to eight days. Preclinical research suggests it engages the GHRH receptor with equivalent agonist activity to native GHRH, making it a useful tool compound for studying sustained GH axis stimulation in research settings.
DAC stands for Drug Affinity Complex — a maleimido propionic acid moiety conjugated to a lysine residue that enables reversible covalent binding to circulating serum albumin. Because albumin has a plasma half-life of approximately 19 days in humans, albumin-bound peptides benefit from markedly extended circulatory persistence. In preclinical pharmacokinetic studies, the DAC modification on CJC-1295 has been reported to extend the effective half-life to approximately six to eight days, converting it from a pulsatile GH secretagogue into a sustained-release GHRH agonist relevant to chronic axis stimulation models.
Research in rodent models demonstrates that CJC-1295 administration produces dose-dependent, sustained elevations in circulating IGF-1, the primary somatomedin mediating anabolic GH signaling at peripheral tissues. Teichman SL et al. (2006) reported mean IGF-1 increases of 30–70% above baseline sustained for up to 28 days following a single injection of CJC-1295 DAC in study participants — a pharmacodynamic profile consistent with its extended half-life. Animal model studies have used these IGF-1 elevations as a biomarker for downstream somatotropic axis activation when investigating body composition and metabolic endpoints.
Preclinical research on the GH/IGF-1 axis and mammalian longevity presents a nuanced picture: genetic models with suppressed somatotropic signaling (GHR-KO, Ames dwarf mice) display extended lifespan, while age-related decline in GH pulse amplitude is associated with adverse metabolic and body composition changes. CJC-1295, as a GHRH receptor agonist, serves as a pharmacological probe for examining what restoration of youthful GH secretory dynamics produces in aged rodent models — a research question with relevance to the broader aging biology field. It is important to note that this remains an area of active preclinical investigation and no clinical conclusions should be drawn.
The two forms differ primarily in pharmacokinetic profile and the resulting GH secretory pattern they produce. CJC-1295 without DAC (Modified GRF 1-29) generates a discrete, transient GH pulse resembling physiological pulsatile release — making it appropriate for studies examining acute secretory dynamics or pulsatile GH signaling. CJC-1295 with DAC produces a prolonged mean GH and IGF-1 elevation over days, better suited for models examining chronic somatotropic axis stimulation, body composition endpoints, or metabolic adaptation over time. Researchers select between forms based on the specific axis behavior being investigated.
The foundational pharmacokinetic and pharmacodynamic characterization of CJC-1295 appears in: Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. Additional mechanistic context is provided by Alba M et al., who examined GHRH analog pharmacology in murine models, and by Ionescu M & Frohman LA, who reviewed GHRH receptor signaling and its role in the somatotropic axis in Endocrine Reviews (2006).
View CJC-1295 research compound →
Each compound available on biohacker.team is verified by our specialist research team through independent third-party HPLC authentication, with batch-level certificates of analysis published openly. Our experts cross-reference purity data against established preclinical literature before each batch is listed.
This article is for informational and educational purposes only. All compounds discussed are intended strictly for laboratory and scientific research use. Not for human consumption. Not for sale to the public.